EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19
Study Details
Study Description
Brief Summary
This study is clinical trial (intervention study with external comparison group) to test vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, including all adults aged 18 to 49 years from Viana city - Espírito Santo (ES)/Brazil, on the incidence of new cases over 12 months following treatment, compared to an external group from same state and adjusted for socio-demographic and epidemiological variables.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2/Phase 3 |
Detailed Description
This study is clinical trial (intervention study with external comparison group) to test vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, including all adults aged 18 to 49 years from Viana city - Espírito Santo (ES)/Brazil, on the incidence of new cases over 12 months following treatment, compared to an external group from same state and adjusted for socio-demographic and epidemiological variables. Cellular and humoral immunity will be studied in a representative sub-sample compared to an external reference group (cohort of health workers) vaccinated with standard dose. The outcomes will be evaluated at 28 days after the second dose and follow-up after 6 months and 12 months. The main outcome will be to decrease in 60% the incidence of new cases over 6 months after receiving the vaccine. The clinical epidemiological variables will be obtained from e-SUS VS, e-SUS notifica and datasus: number of cases, number of deaths with specific ICD for covid-19, number of hospital admissions for covid-19; number of ICU admissions for the treatment of SARS, total number of tests (RT-PCR) performed and positive. The cellular and humoral immune response will be assessed by viral neutralization assay (neutralizing antibody test), serological assay by chemiluminescence, determination of specific IgM and IgG profiles, measurement of systemic soluble factors (chemokines, cytokines and growth factors), stimulation antigen-specific peripheral blood mononuclear cells in vitro and investigation of memory T and B lymphocytes and intracytoplasmic cytokines. It is estimated to include 29,637 people in the study, to reach 85% vaccination cover of individuals aged 18-49 years. The subsample size immunogenicity test is 600 individuals from the eligible population, estimating losses of 15% and study power of 90%, alpha error of 1%. The hypothesis of the study is that the reduction in the incidence of covid-19 and the cellular and humoral immune response achieved with a half dose will be similar to the reduction expected with the standard dose.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Group 1 Half dose of ChAdOx1 nCoV-19 (AZD1222) ) in a 2-dose schedule with an interval of 8 weeks. |
Biological: Half dose of ChAdOx1 nCoV-19 (AZD1222)
Vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, including all adults aged 18 to 49 years, from non-priority groups, from Viana city - Espírito Santo (ES)/Brazil.
|
| Active Comparator: Group 2 Standad dose of ChAdOx1 nCoV-19 (AZD1222) in a 2-dose schedule with an interval of 8 weeks. |
Biological: Standard dose of ChAdOx1 nCoV-19 (AZD1222)
Vaccination with standad dose of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, in external cohort of health workers aged 18 to 49 years.
|
Outcome Measures
Primary Outcome Measures
- Incidence of new cases [12 months]
Incidence of new cases over 12 months following treatment
Secondary Outcome Measures
- Number of deaths [12 months]
Number of deaths with specific ICD for covid-19
- number of hospital admissions [12 months]
number of hospital admissions for covid-19
- number of intensive care unit (ICU) admissions [12 months]
number of intensive care unit (ICU) admissions for the treatment of SARS
- number of tests (RT-PCR) [12 months]
number of tests (RT-PCR) performed and positive
- Viral Neutralization Assay [4 and 8 months]
Neutralizing antibody titers will be expressed by the ability of antibodies to neutralize up to 50% the number of plaques (PRNT50). Title > 1:50 will be considered positive.
- serological assay [8 and 10 months]
Serological test by chemiluminescence. Results are expressed in U/mL and data interpretation will be done as follows: <0.8 U/mL = non-reactive sample; ≥0.8 U/mL = reactive sample.
- IgM [8 and 10 months]
Determination of specific IgM profile. Results will be expressed in fluorescence intensity or pg/ml.
- IgG [8 and 10 months]
Determination of specific IgG profile. Results will be expressed in fluorescence intensity or pg/ml.
- systemic soluble factors [8 and 10 months]
Dosage of soluble systemic factors (chemokines, cytokines and growth factors). Results will be expressed in pg/ml.
- Antigen-specific stimulation of peripheral blood mononuclear cells [10 and 12 months]
Antigen-specific stimulation of peripheral blood mononuclear cells in vitro. The results will be expressed in percentage positive frequency for a specific cell phenotype.
- Lymphocyte investigation [10 and 12 months]
Investigation of memory T and B lymphocytes. The results will be expressed in percentage positive frequency for a specific cell phenotype.
- Cytokine investigation [10 and 12 months]
Investigation of intracytoplasmic cytokines. The results will be expressed in percentage positive frequency for a specific cell phenotype.
Other Outcome Measures
- Adverse events [14 months]
All adverse events will be followed up to establish severity and causal correlation. There will be surveillance of deaths and will be reported to the ethics committee.
Eligibility Criteria
Criteria
Inclusion Criteria:
- residents of Viana, Espírito Santo, aged between 18 and 49 years
Exclusion Criteria:
-
Pregnant women;
-
History of severe allergic reaction (anaphylaxis) to any previously administered vaccine;
-
Having received another vaccine in the last 14 days;
-
Belonging to a priority risk group for vaccination, as per the PNI recommendations;
-
Have fever or flu-like symptoms;
-
Have previously received any vaccine for covid-19 at any time;
-
Recent diagnosis of covid-19 with onset of symptoms 28 days before vaccination;
-
Disorders of coagulation and use of anticoagulants.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Federal University of Espirito Santo | Vitória | Espirito Santo | Brazil | 29041-295 |
Sponsors and Collaborators
- Federal University of Espirito Santo
- Instituto René Rachou/Fiocruz
- Escola Nacional de Saúde Pública Sérgio Arouca/Fiocruz
- Programa de Computação Científica/Fiocruz
- Escola Superior de Ciências da Santa Casa de Misericórdia de Vitória
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- FUES02